JAC Advance Access originally published online on July 7, 2008
Journal of Antimicrobial Chemotherapy 2008 62(4):762-765; doi:10.1093/jac/dkn276
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin
1 Department of Microbiology, Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK 2 Department of Microbiology, The General Infirmary, Old Medical School, Leeds LS1 3EX, UK
Received 16 April 2008; returned 5 June 2008; revised 10 June 2008; accepted 11 June 2008
* Corresponding author. Tel: +44-113-3926818; Fax: +44-113-3435649; E-mail: mark.wilcox{at}leedsth.nhs.uk
Objectives: Clostridium difficile infection is a nosocomial disease of increasing importance. First-line treatment is limited to metronidazole or vancomycin. Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, including drug-resistant pathogens. MICs of oritavancin, metronidazole and vancomycin for genotypically distinct C. difficile strains, including epidemic C. difficile PCR ribotypes 001 and 027, were determined by agar incorporation and broth macrodilution methods. In agar incorporation methods, the impact of supplements on oritavancin MICs was tested to address oritavancin binding to surfaces.
Methods: Thirty-three genotypically distinct C. difficile strains were identified by PCR ribotyping. Wilkins Chalgren agar incorporation plates containing oritavancin, metronidazole and vancomycin were prepared with and without 0.002% polysorbate-80 (P80) and lysed horse blood (2%). Broth macrodilution MICs of oritavancin, metronidazole and vancomycin were determined in Brucella broth. Inoculated agar incorporation plates and broth macrodilution tubes were cultured anaerobically at 37°C for 48 h.
Results: Broth macrodilution MICs were lower than agar incorporation MICs for oritavancin, but not for metronidazole and vancomycin. Oritavancin broth macrodilution MIC90s were 2- to 4-fold lower than the corresponding agar incorporation MIC90s, while geometric mean MICs were >5-fold lower. Oritavancin broth macrodilution MIC90s were 
2- and 5-fold lower than those for metronidazole and vancomycin. Metronidazole was the most active antimicrobial agent against C. difficile using agar incorporation methods. Oritavancin agar incorporation MIC90s were unaffected by 0.002% P80 and/or 2% lysed horse blood.
Conclusions: Oritavancin was at least 4-fold more potent than vancomycin against the majority (25/33) of C. difficile strains tested by broth macrodilution. Oritavancin activity may be underestimated by agar incorporation methods, regardless of the use of P80 or lysed horse blood.
Keywords: C. difficile , susceptibility , oritavancin , metronidazole , vancomycin , ribotyping
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. M. Williams and R. C. Spencer The management of Clostridium difficile infection Br. Med. Bull., June 8, 2009; (2009) ldp021v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Baines, R. O'Connor, K. Saxton, J. Freeman, and M. H. Wilcox Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model J. Antimicrob. Chemother., November 1, 2008; 62(5): 1078 - 1085. [Abstract] [Full Text] [PDF]
|
|